SKAN Group AG (XSWX:SKAN) (Q2 2025) Earnings Call Highlights: Navigating Challenges with ...

This article first appeared on GuruFocus.

Order Backlog: Record high at CHF386.4 million. Net Sales: 17% behind plan due to project postponements. EBITDA: Declined to CHF0.9 million from CHF21 million in the previous year. EBITDA Margin: Very low due to missing top line. Investments: CHF21.5 million mainly into pre-approved services. Order Intake Growth: 20.2% increase, driven by ADC filling lines. Book-to-Bill Ratio: 1.6, indicating good future sales visibility. Net Cash Position: CHF43 million. Equity Ratio: 48.1%. Operating Cash Flow: CHF23 million. Free Cash Flow: Increased to CHF9.2 million from a negative CHF29.5 million. Employee Growth: 33 new hires. Other Operating Expenses: Increased to CHF26.1 million from CHF22 million. Service and Consumables EBITDA: Declined from CHF12.6 million to CHF10 million.

Warning! GuruFocus has detected 1 Warning Sign with XSWX:SKAN.

Release Date: August 19, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

SKAN Group AG (XSWX:SKAN) reported a significant increase in order intake, with a 20% growth compared to the previous half-year, driven by demand in the pharmaceutical market. The company has a record-high order backlog of CHF386.4 million, providing strong visibility for future sales. SKAN Group AG has completed two strategic acquisitions, ABC Transfer and Medtronic, which align with their strategy to expand aftermarket service and digital integration offerings. The company continues to invest in strategic initiatives, with CHF21.5 million invested in pre-approved services, maintaining a focus on future growth. SKAN Group AG's financial structure remains solid with a net cash position of CHF43 million and an equity ratio of 48.1%, supporting future growth and acquisitions.

Negative Points

Net sales are 17% behind plan due to project postponements, particularly in vaccine filling lines and a major GLP1 project. The EBITDA margin is low, impacted by the missing top line and project delays, resulting in a decline from CHF21 million to CHF0.9 million. The company faces challenges with the cyclical and lumpy nature of its business, exacerbated by the accumulation of project postponements. There is a risk of further postponements or cancellations of vaccine projects, which could impact future revenue. The geopolitical situation and tariffs in the US market pose potential challenges, although SKAN Group AG has strategies in place to mitigate these risks.

Q & A Highlights

Q: Can you clarify the guidance for the year, particularly regarding the M&A contribution from Medtronic and whether the growth guidance includes currency effects? A: Thomas Huber, CEO, explained that the guidance can be achieved with organic growth, and the Medtronic acquisition provides additional comfort in reaching it. The guidance does not specify currency effects, but currency impacts are acknowledged. The guidance is set at mid-teens growth, which is a broad range.

Story Continues

Q: How much revenue contribution do you expect from the pre-produced standard isolators in the second half? A: Thomas Huber, CEO, stated that the pre-produced isolators are expected to sell within the year, as they are standardized models with consistent demand. The pre-production will help achieve the guidance by converting current costs into revenue and profit once purchase orders are received.

Q: Can you provide more details on the ABC Transfer acquisition and its expected revenue development? A: Thomas Huber, CEO, noted that ABC Transfer is currently a small acquisition in terms of revenue. The company has validated products with major customers and is at the stage of ramping up production. SKAN Group sees synergies in producing beta bags in their facilities, which will aid in scaling up without significant new investments.

Q: Are the postponed projects still included in the backlog, and what is the risk of further postponements or cancellations? A: Thomas Huber, CEO, confirmed that postponed projects remain in the backlog unless canceled. About 60 projects were postponed, with five canceled. The backlog includes CHF40 million of delayed projects expected to resume in 2026 and 2027. The risk of cancellations exists, but financial impacts are mitigated by cancellation fees.

Q: What is the outlook for the North American market, and are there plans for a new facility there? A: Thomas Huber, CEO, mentioned that there is renewed activity in North America, with greenfield projects resuming. SKAN is exploring facility options to ramp up production slowly, starting with small isolators. The goal is to maintain quality while gradually increasing local manufacturing capabilities.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

View Comments